Peptide record

TPDB04540

Nisin Z Antibacterial Anticancer Antifungal Antiparasitic standard
34 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB04540
Nisin Z
Antibacterial Anticancer Antifungal Antiparasitic
Anti-infective peptides Cancer-related peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept
standard
No
A 34-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C141H245N41O46S7
RDEQFWY
CT
3475.16
8.48
4
0
10
+3
0.44
0.406
71.76
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
250
0.07
16
Residue Composition
number
2
A
0
R
2
N
0
D
5
C
0
E
0
Q
3
G
1
H
3
I
2
L
3
K
2
M
0
F
1
P
4
S
5
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 2 D: 0 C: 5 E: 0 Q: 0 G: 3 H: 1 I: 3 L: 2 K: 3 M: 2 F: 0 P: 1 S: 4 T: 5 W: 0 Y: 0 V: 1
Chemical Descriptors
34 reviewed residue count
C141H245N41O46S7 sequence-only estimate (linear, free termini)
3475.16 sequence-only estimate (linear, free termini)
8.48 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
0.44 sequence-only estimate (linear, free termini)
0.406 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Linear Activity
Free Activity
Antimicrobial and Anticancer Activity
Lactococcus lactis Activity
Evidence Records 17 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.02 µg/mL

Target

L. lactis MG1363

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6
Evidence 2 Activity

Activity

MIC
Antibacterial
1.5-12.5 µg/mL

Target

L. monocytogenes LMG10470 or TT82E or LK132

Source & Reference

dbAMP DRAMP

Other

active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml
Evidence 3 Activity

Activity

MIC
Antibacterial
6.25 µg/mL

Target

B. cereus CH-85

Source & Reference

dbAMP DRAMP

Other

G1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG1
Evidence 4 Activity

Activity

MIC
Antibacterial
6.25 µg/mL

Target

Staphylococcus aureus LMG10147 or LMG15975 or MRSA

Source & Reference

dbAMP DRAMP

Other

ogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al.,
Evidence 5 Activity

Activity

MIC
Antibacterial
3.13 µg/mL

Target

E. faecium LMG11423 or LMG16003 or LMG16216

Source & Reference

dbAMP DRAMP

Other

reus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al., 2024 . Antivirus: Nisin was found to interact with the SARS-CoV-2
Evidence 6 Activity

Activity

IC50
IC50 = 188.5 ± 8.7 µM
Anticancer
188.5

Target

Skin Cancer
A-375
Skin

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 7 Activity

Activity

60% LDH release at 60 µM
Anticancer

Target

Skin Cancer
A-375
Skin

Assay & Model

LDH leakage assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2018
Evidence 8 Activity

Activity

MIC
Antifungal
0.02 µg/mL

Target

L. lactis MG1363

Source & Reference

dbAMP DRAMP Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6
Evidence 9 Activity

Activity

MIC
Antifungal
1.5-12.5 µg/mL

Target

L. monocytogenes LMG10470 or TT82E or LK132

Source & Reference

dbAMP DRAMP Antifungipept

Other

active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml
Evidence 10 Activity

Activity

MIC
Antifungal
6.25 µg/mL

Target

B. cereus CH-85

Source & Reference

dbAMP DRAMP Antifungipept

Other

G1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG1
Evidence 11 Activity

Activity

MIC
Antifungal
6.25 µg/mL

Target

Staphylococcus aureus LMG10147 or LMG15975 or MRSA

Source & Reference

dbAMP DRAMP Antifungipept

Other

ogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al.,
Evidence 12 Activity

Activity

MIC
Antifungal
3.13 µg/mL

Target

E. faecium LMG11423 or LMG16003 or LMG16216

Source & Reference

dbAMP DRAMP Antifungipept

Other

reus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al., 2024 . Antivirus: Nisin was found to interact with the SARS-CoV-2
Evidence 13 Activity

Activity

MIC
Antiparasitic
0.02 µg/mL

Target

L. lactis MG1363

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6
Evidence 14 Activity

Activity

MIC
Antiparasitic
1.5-12.5 µg/mL

Target

L. monocytogenes LMG10470 or TT82E or LK132

Source & Reference

DRAMP

Other

active against L. lactis MG1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml
Evidence 15 Activity

Activity

MIC
Antiparasitic
6.25 µg/mL

Target

B. cereus CH-85

Source & Reference

DRAMP

Other

G1363 (MIC 0.02 ug/ml), L. monocytogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG1
Evidence 16 Activity

Activity

MIC
Antiparasitic
6.25 µg/mL

Target

Staphylococcus aureus LMG10147 or LMG15975 or MRSA

Source & Reference

DRAMP

Other

ogenes LMG10470 or TT82E or LK132 (MIC 1.5-12.5 ug/ml), B. cereus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al.,
Evidence 17 Activity

Activity

MIC
Antiparasitic
3.13 µg/mL

Target

E. faecium LMG11423 or LMG16003 or LMG16216

Source & Reference

DRAMP

Other

reus CH-85 (MIC 6.25 ug/ml), S. aureus LMG10147 or LMG15975 or MRSA (MIC 6.25 ug/ml), and E. faecium LMG11423 or LMG16003 or LMG16216 (MIC 3.13 ug/ml) anti-VRE ( Guo et al., 2024 . Antivirus: Nisin was found to interact with the SARS-CoV-2